We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer.
- Authors
Johung, Kimberly; Rewari, Amar; Wu, Hao; Judson, Benjamin; Contessa, Joseph N.; Haffty, Bruce G.; Decker, Roy H.
- Abstract
Background High expression of excision repair cross-complementation 1 (ERCC1) predicts for resistance to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone. Methods ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays constructed from 123 patients with stages I-II laryngeal squamous cell carcinoma treated with standard radiotherapy. Results ERCC1 expression did not correlate with clinicopathologic risk factors, local control, or overall survival. At 5 years, local control was 75% versus 71% ( p = .78) and overall survival was 68% versus 54% ( p = .65), for nonexpressors and expressors of ERCC1, respectively. On multivariate analysis, T classification predicted for local control, and T classification and age predicted for overall survival. Conclusions ERCC1 expression did not predict for radiotherapy resistance or worse survival. Therefore, radiotherapy remains an effective treatment in tumors with high ERCC1 expression. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
- Subjects
SURGICAL excision; RADIOTHERAPY; LARYNGEAL cancer; CANCER chemotherapy; CANCER risk factors; MULTIVARIATE analysis
- Publication
Head & Neck, 2013, Vol 35, Issue 6, p852
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.23041